As the science stands, the vast majority of the roughly eight million people in South Africa living with HIV will have to get ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...
The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.
The Ochsner Transplant Institute served as one of 26 U.S. transplant centers collaborating in an HIV-to-HIV kidney transplant study ...
Proof-of-Concept Study to Find Functional Cure for HIV July 24, 2024 — Researchers conducted a breakthrough proof-of-concept study that found an HIV-like virus particle that could cease the need ...
A virologist at the University of Nebraska-Lincoln, Qingsheng Li, was awarded $3.5 million to advance his work on a vaccine ...
Researchers remain hopeful that they're heading in the right direction to finding a cure for HIV, the virus that causes AIDS. Right now, it’s still out of reach. But the unusual cases of four ...
The Wall Street Journal on MSN12d
GSK Profit Rises on HIV, Cancer Treatments But Sales Slip on Weak U.S. Vaccine DemandGSK reiterated its full-year guidance after its new HIV and cancer treatments lifted profit ahead of analysts’ expectations ...
Raltegravir Tablets USP, 600 mg are indicated in combination with other antiretroviral agents for the treatment of human ...
Nebraska Aids Project is celebrating 40 years with its annual Night of a Thousand Stars fundraiser. The gala will contribute ...
Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...
Identifying best practices that will prevent HCV transmission in MSM with HIV is needed to reduce HCV reinfection rates in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback